{"id":"3aps","safety":{"commonSideEffects":[{"rate":null,"effect":"Dysgeusia (taste disturbance)"},{"rate":null,"effect":"Hypogeusia (reduced taste sensation)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"3APS inhibits P2X3 purinergic receptors on vagal sensory neurons, which are involved in the cough reflex pathway. By blocking these receptors, the drug reduces the hypersensitivity of cough-mediating neurons, thereby decreasing cough frequency and severity in patients with chronic cough conditions.","oneSentence":"3APS is a selective P2X3 receptor antagonist that blocks pain signaling in sensory neurons to reduce chronic cough.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:57:15.038Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic cough (idiopathic pulmonary fibrosis-associated cough)"},{"name":"Refractory chronic cough"}]},"trialDetails":[{"nctId":"NCT00217763","phase":"PHASE3","title":"European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients","status":"UNKNOWN","sponsor":"Bellus Health Inc. - a GSK company","startDate":"2005-09","conditions":"Alzheimer's Disease","enrollment":930},{"nctId":"NCT00314912","phase":"PHASE3","title":"Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease","status":"UNKNOWN","sponsor":"Bellus Health Inc. - a GSK company","startDate":"2006-05","conditions":"Alzheimer's Disease","enrollment":650},{"nctId":"NCT00088673","phase":"PHASE3","title":"Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease","status":"UNKNOWN","sponsor":"Bellus Health Inc. - a GSK company","startDate":"2004-06","conditions":"Alzheimer Disease","enrollment":950}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":55,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"3APS","genericName":"3APS","companyName":"Bellus Health Inc. - a GSK company","companyId":"bellus-health-inc-a-gsk-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"3APS is a selective P2X3 receptor antagonist that blocks pain signaling in sensory neurons to reduce chronic cough. Used for Chronic cough (idiopathic pulmonary fibrosis-associated cough), Refractory chronic cough.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}